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Introduction
Seizures is defined as the malfunction of the
brain’s electrical system originated from the evacu-
ation of cerebral cortex neurons. Its signs and
symptoms include lack of awareness or change in
consciousness, involuntary movements, and
changes in perceptions, behaviors, and feelings(1).
Seizure is the most common treatable neurological
disorder in childhood occurred by a wide range of
different diseases involving the nervous system(2, 3).
Seizure with prevalence of 4 to 6 cases in 1000
children, are considered as the most common neu-
rological disorder in pediatrics(4). Five million peo-
ple worldwide suffer from epilepsy in which 3 mil-
lion of them are children and 90% of these children
live in developing countries(5).
Phenobarbital is one of the oldest, safest, and
least expensive used drugs in the treatment of
seizure disorders(6). This drug has been introduced
by the WHO as first-line treatment for generalized
tonic-clonic and partial seizures in developing
countries(7, 8). However, the use of phenobarbital for
febrile seizures in children due to reported behav-
ioral problems is under discussion and its consump-
tion in developed countries regarding newer drugs
with fewer effects on behavioral functions is declin-
ing(9). Also, when other drugs are contraindicated
due to serious hematologic or hepatic side effects,
phenobarbital can be a first-line treatment especial-
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ABSTRACT
Objectives: Behavioral problems are considered as the side effects of phenobarbital consumption in children. Thus, the aim of
this research is studying the effect of vitamin B6 on behavioral disorders due to use of phenobarbital in patients with seizure.
Patients and methods: In this study, 77 patients (Children with Seizures) were studied and divided to needs to be removed two
groups. Phenobarbital along with vitamin B6, and phenobarbital along with a placebo were separately prescribed to the two groups
for three months, and behavioral changes were recorded and the data were collected and provided for the statistical software.
Results: In the first three months, no significant difference was observed between the two groups, and in the second three
months, the average value of hyperactivity behavior removed significantly decreased. In the drug group in the first three months and
placebo group in the second three months, hyperactivity and aggressive behaviors significantly reduced moreover, With respect to all
three behaviors, the placebo group in the first three months and drug group in the second three months the Were not significantly dif-
ferent. 
Conclusion: vitamin B6 can be effective in the reduction of hyperactivity behavior in the children. 
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ly when drug price is a primary concern(8, 10).
Behavioral problems mentioned as side effects of
phenobarbital include hyperactivity, aggressive
behavior, inattention, and restlessness(11). Sylvia et
al. (1995) indicated that 60% of children, receiving
phenobarbital to treat febrile seizure, suffer from
behavioral problems that led to The discontinuation
of treatment(12). The incidence of behavioral prob-
lems in children with epilepsy is two times higher
than children with chronic disease that does not
involve the central nervous system and it is four
times more than healthy children(13-16). Behavioral
problems in 20 to 50% of children with febrile
seizure, receiving phenobarbital, have been report-
ed and led to be discontinuation of treatment in 20
to 30% of them(11). Also, the prevalence of behav-
ioral disorders originated from phenobarbital in
patients with mental retardation and developmental
disorders is considerably high(17).
many studies have been done on the effect of
vitamin B6 in behavioral disorders in autistic
patients, panic attacks, and ADHD and etc. and Its
positive effects on behavioral disorders have been
reported given the use of levetiracetam in children
with elipsy(18-21), this study work aims to investigate
the effect of vitamin B6 on behavioral disorders due
to use of phenobarbital in epileptic patients ages 2
to 15 years treated with this drug.
Materials and methods
This Study is a double-blind randomized One.
The Statistical society includes all patients with
seizures between 2 and 15 years of PHE consump-
tion In this study77 people were enrolled and divid-
ed into two intervention groups with drug (41
patients) and placebo (n = 36). The available sam-
pling method was used in this study. The method
reported by Kelsey and et al.(22) has been applied to
obtain a sample size of each group. Required data
was collected through the Conner’s parent rating
scale questionnaire(23) that has the high validity and
has been regarded A standard test. Conners and et
al. have reported the reliability and validity of this
scale Is equal to to 0.9. Additionally, and the validi-
ty of this questionnaire have been reported As to
0.85 by the Institute of Cognitive Science(24). Here,
8 cases of Conners questionnaire have been consid-
ered in which 3, 3, and 2 cases are in relation to
Hyperactivity behavior, aggression, and attention
deficit, respectively. Patients’ followup was done
through phone calls and resourcing patients accom-
pany with parents to the medical center. Patients
have had no history of Anticonvulsants (phenobar-
bital) consumption. Patients 2 to 15 years old with
seizure disorders were randomly assigned to two
groups receiving drug (B6) and placebo. Factors
such as gender, family history, history of drug etc.
Have not been included in the study. The excluded
factors included background psychological disor-
ders (SADS-KIDS), background disease, and disin-
clination to enter the study. 
In the first three months of study, a drug was
given to a group and a placebo to the other group.
After 10 days of washed out, the place of the two
groups were replaced and then the treatment was
carried out for three months, again. At the end of
each study, the data was collected by filling out a
questionnaire and data analysis was performed
using SPSS software. To test the hypothesis, T-test
and Chi- square statistical methods were used.
Phenobarbital: Phenobarbital is one of the
sedative drugs has been widely used for the treat-
ment of various forms of epilepsy, especially in
children. There are tablets 15, 60 and 100 mg, and
vials 100 and 200 mL of Phenobarbital. The onset
of this drug varies from 10 minutes (IV administra-
tion) to 60 minutes (oral administration), and dura-
tion of drug action varies from 4 hours to less than
6 hours. Its half-life is generally 50 - 140 hours (6, 25).
Vitamin B6: Vitamin B6 is one of the water
soluble vitamins that plays a critical role in the pro-
tein metabolism and adjusting the nervous system
of the human body. This vitamin is found in the
food plants and animals, but biologically, its animal
sources are numerous. There are tablet 40 mg, and
vials 50, 100 and 150 mL of B6 vitamin, and its
half-life is generally 15 - 20 days. Vitamin B6 used
in the present study contains a dose 100 - 150 mg,
and placebo purchased from Osvah Pharmaceutical
Company was used (26-29).
Behavioral disorders are different groups of
extremist and deviant behaviors through which the
patients repeatedly violate the basic rights of others.
These disorders occur in childhood or adolescence,
and are more common in boys regarding to girls.
Behavioral problems originated from phenobarbital
consumption include hyperactivity, aggressive
behavior, inattention and restlessness(30).
Results
The study population included two groups
(placebo and control) that first group received
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Phenobarbital along with vitamin B6 for three
months. After 10 days, this group received placebo
instead of vitamin B6 for other three months. The
second group received Phenobarbital along with
placebo for three months. After 10 days, this group
received vitamin B6 instead of placebo for other
three months. 
77 patients with epilepsy were enrolled in this
study. 40 patients were female and 37 were male.
Also, 41 patients with a mean age of 39.19 ± 11.55
months received Phenobarbital along with vitamin
B6 in first three months and 36 patients with a
mean age of 37.4 ± 10.41 received Phenobarbital
along with placebo in first three months. The aver-
age age of both groups was not significantly differ-
ent (p = 0.49).
The results regarding to hyperactivity behav-
ioral disorders, originated from the statistical analy-
sis of data obtained from variables such as hyperac-
tivity, Removed running or jumping in a difficult
position and difficult to control in the field of in
Both drug and placebo receiving groups for first
three months, indicated that there was a significant
difference between the two groups (p-value = 0.8).
According to results regarding to attention
deficit behavioral disorders that was the sum of
data obtained from variables such as “walking in
class and attention deficit” and “distraction at work-
ing”, no significant difference between these groups
was observed for first three months. Also, the
results obtained from aggressive behavior disor-
ders, originated from the statistical analysis of data
of variables such as “anger”, “head banging” and
“biting” showed no significant difference between
the drug and placebo receiving groups.
In the second three months, the results
obtained from data analysis regarding to attention
deficit (p-value 0.14) and aggression (p-value 0.6)
behaviors using T-test showed no significant differ-
ence between drug and placebo receiving groups.
Contrarily, the difference between these groups was
significant (p-value 0.01) in the field of hyperactiv-
ity behavior disorder and the average of all three
indexes was higher in the placebo receiving groups.
Using Paired Sample T-Test, in the field of
attention deficit behavioral disorder between drug
receiving group in the first three months and place-
bo receiving group in the second three months was
observed no significant difference (p-value 0.15).
But, in regard with hyperactivity (p-value 0.001)
and aggression (p-value 0.01), the difference
between these groups was significant, and the aver-
age of all three indexes was higher in the placebo
receiving groups. 
Using Paired Sample T-Test, in the field of
attention deficit (p-value 0.58), hyperactivity (p-
value 0.65) and aggression (p-value 0.88) behav-
ioral disorders between placebo receiving group in
the first three months and drug receiving group in
the second three months, no significant difference
was observed. It’s noteworthy that the average of
all three indexes was higher in the placebo receiv-
ing groups. 
Discussion
The effect of vitamin B6 consumption on the
behavioral problems due to levetiracetam drug con-
sumption has been studied by Major et al(18). They
investigated the influence of pyridoxine supplement
(vitamin B6) on the behavioral side effects originat-
ed from levetiracetam consumption in the children.
The behavioral side effects related to the use of lev-
etiracetam in epilepsy are being recognized. The
improvement of behavioral side effects related to
the use of levetiracetam was observed after the con-
sumption of vitamin B6. 
The investigation of the behavioral problems
related to the consumption of phenobarbital in the
hyperactivity, attention deficit, and aggression
behavioral disorders was performed by completing
the questionnaire; including eight variables to eval-
uate each of above factors. To investigate hyperac-
tivity behavioral disorder due to the consumption of
phenobarbital, questionnaire variables include
“hyperactivity”, “running or jumping in a difficult
position” and “difficult to control”.
In the first three months of treatment, the com-
parison of the vitamins B6 drug receiving group
and placebo receiving group showed that the aver-
age of each three variables in the drug receiving
group was higher than that of placebo receiving
group and the difference was not statistically signif-
icant. After 10 days of The discontinuation of vita-
min B6 and the change of drug receiving group
with placebo receiving group, , the average of each
three variables related to hyperactivity was lower in
the drug receiving group in the second three
months. The difference between two groups was
significant statistically.
The researchers(31) mentioned that the behav-
ioral disorders such as hyperactivity occur by mak-
ing disorder in the vitamin B6 receptors. Also, the
removing substances that inhibit the absorption of
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vitamin B6, improves the symptoms of hyperactivi-
ty. Contrarily, the results obtained from the investi-
gation of hyperactivity behavior in first three
months indicate that the average of hyperactivity
was higher in the drug receiving group while there
was no significant difference compared to the con-
trol group. However, in the second three months,
the average of hyperactivity was increased in the
placebo receiving group. Also, in comparison with
hyperactivity behavior in the first three months, the
drug receiving group showed statistically signifi-
cant difference. Comparing the placebo receiving
group at first three months and drug receiving
group at second three months, it can be concluded
that this difference may be attributed to the
enhancement of symptoms resulted from the dis-
continuation of vitamin B6, and a positive effect of
vitamin B6 on the significant decrease of the hyper-
active behavior. The comparison of this study with
previous studies such as levetiracetam consumption
along with vitamin B6, showed that the use of vita-
min B6 can strictly diminish the symptoms of
hyperactivity (scheme 1).
Attention deficit behavior includes variables
such as walking in class, attention deficit and dis-
traction at working in the questionnaire. In the first
three months, the average of each three variables in
the drug-receiving group is lower than that of
placebo-receiving group while the difference
between two groups was not statistically signifi-
cant. Also, In the second three months and after
switching the drug-receiving group with placebo-
receiving group, the average of each three variables
is lower in the drug-receiving group while the dif-
ference between two groups was not statistically
significant either. In the general investigation of
attention deficit behavior due to the use of pheno-
barbital along vitamin B6, the average of each three
variables was lower in the drug-receiving group
while no significant difference was observed
between these groups. It can be concluded that the
vitamin B6 consumption has lower effect on the
decrease of attention deficit in the children (scheme
2).
Aggressive behavior is one the side effects of
the use of phenobarbital that has been Studied by
variables such as madness, head slamming, and bit-
ing after treatment with the drug and placebo in the
groups. It was observed that the average of each
three variables in the drug-receiving group is lower
than that of placebo-receiving group In the first
three months. The significant difference was
observed between two groups which only in the
head slamming variable. At the second three
months, the average of each of two variables,
including madness and biting was higher in the
placebo-receiving group, while the average of head
banging variable was higher in the drug-receiving
group, which at the second three months, this dif-
ference between any of the variables was not signif-
icant. In the general investigation of aggressive
behavior at the first and second three months, aver-
age increase and significant difference were only
observed in the drug-receiving group at the first
three months and placebo-receiving group at the
second three months. Thus, it can be said that dis-
continuation of vitamin B6 enhances symptoms
(scheme 3).
Conclusion
The results indicated that the hyperactivity
behavior was lower in the vitamin B6-receiving
group, and this drug diminishes the hyperactivity
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Scheme 1: The influence of phenobarbital on the hyperactivity.
behavior in the children treated with phenobarbital.
Also, the enhancement of symptoms was observed
owing to the discontinuation of vitamin B6. Also, it
was observed that the use of vitamin B6 is not
effective in reducing attention deficit behavior due
to phenobarbital consumption. Finally, results con-
firmed that the use of vitamin B6 is not effective in
reducing aggressive behavior due to phenobarbital
consumption, and complete discontinuation of vita-
min B6 after a course of treatment enhances this
behavior in the children.
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